Immunotherapy Combo Treatment Improves Progression-Free Survival in Triple-Negative Breast Cancer
July 3rd 2018Atezolizumab (Tecentriq, Roche) plus chemotherapy nab-paclitaxel (Abraxane) met its co-primary endpoint of progression-free survival in patients with metastatic triple-negative breast cancer.
Read More